Holen Sie sich die Stockscreener-App
33.40
1.18%
-0.40
Vorhandelsmarkt:
33.38
-0.02
-0.06%
Schlusskurs vom Vortag:
$33.80
Offen:
$34.12
24-Stunden-Volumen:
436.48K
Relative Volume:
1.20
Marktkapitalisierung:
$231.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.46M
KGV:
-20.37
EPS:
-1.64
Netto-Cashflow:
$-99.89M
1W Leistung:
-14.93%
1M Leistung:
-15.66%
6M Leistung:
+203.64%
1J Leistung:
+145.23%
1-Tages-Spanne:
$33.20
$34.63
1-Wochen-Bereich:
$33.20
$42.75
52-Wochen-Spanne:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Vergleichen Sie VOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
33.40 | 231.66M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
Published on: 2025-10-09 02:38:01 - newser.com
Vor biopharma $3.5m stock sale by ten percent owner - Investing.com
Can momentum traders help lift Vor Biopharma Inc.Dividend Hike & Low Risk Investment Opportunities - newser.com
Applying sector rotation models to Vor Biopharma Inc.2025 Key Lessons & Consistent Growth Equity Picks - newser.com
Will Vor Biopharma Inc. bounce back from current support2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com
Relative strength of Vor Biopharma Inc. in sector analysisWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What’s the recovery path for long term holders of Vor Biopharma Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Tick level data insight on Vor Biopharma Inc. volatilityJuly 2025 Sector Moves & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-10-03 00:08:46 - newser.com
What analyst consensus says on Vor Biopharma Inc. stockBull Run & Reliable Volume Spike Trade Alerts - newser.com
Vor Bio Surges: Analysts See Bright Future - timothysykes.com
Published on: 2025-09-30 05:10:46 - newser.com
Vor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46 - Nasdaq
Vor Biopharma | EFFECT: Others - 富途牛牛
Vor Bio Announces Late-Breaking Poster Presentation of - GlobeNewswire
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025 - Yahoo Finance
What drives Vor Biopharma Inc stock priceInsider Trading Activity & Build Diversified Portfolios With Ease - earlytimes.in
Is Vor Biopharma Inc a good long term investmentTrendline Breakouts & Reinvest for Maximum Compounding Returns - Early Times
What analysts say about Vor Biopharma Inc stockMarket Liquidity Analysis & AI-Based Predictions Available Free - earlytimes.in
Published on: 2025-09-27 19:29:37 - newser.com
Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise - Seeking Alpha
Vor Biopharma Shares Slide Following Warrant Registration Filing - MSN
Vor Biopharma stock drops after filing to register warrant shares By Investing.com - Investing.com South Africa
Vor Biopharma stock drops after filing to register warrant shares - Investing.com
Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects By Investing.com - Investing.com South Africa
Vor Biopharma (VOR) Registers 51M Shares for Resale, Warrants in Focus - GuruFocus
Vor Biopharma files for offering of up to 51 million common shares by the selling stockholdersSEC filing - MarketScreener
Vor Biopharma (VOR) files for 51M share offering by selling stockholders - StreetInsider
Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects - Seeking Alpha
Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects - Investing.com India
Stifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to Buy - MarketBeat
Vor Biopharma climbs after Stifel upgrades rating on autoimmune drug potential - TradingView
Vor Biopharma (NYSE:VOR) Stock Price Down 8.6% Following Insider Selling - MarketBeat
Stifel Upgrades Vor Biopharma(VOR.US) to Buy Rating, Raises Target Price to $55 - 富途牛牛
Vor Biopharma’s Strategic Moves and Telitacicept’s Potential Drive Buy Rating Amid Stock Decline - TipRanks
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer - GlobeNewswire
Vor Bio appoints Navid Khan as chief medical affairs officer By Investing.com - Investing.com South Africa
Vor Bio appoints Navid Khan as chief medical affairs officer - Investing.com
Vor Biopharma (VOR) Sees Significant Increase in Borrow Rate - GuruFocus
7 Successful Drug Launches: Vor Bio Taps VYVGART Launch Veteran Navid Khan as Medical Affairs Chief - Stock Titan
Vor Biopharma (NASDAQ:VOR) Shares Down 7.2%What's Next? - MarketBeat
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
4.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):